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Pancreatic cancer stem cells (PaCSCs) drive pancreatic cancer tumorigenesis, chemoresis-
tance and metastasis. While eliminating this subpopulation of cells would theoretically result
in tumor eradication, PaCSCs are extremely plastic and can successfully adapt to targeted
therapies. In this study, we demonstrate that PaCSCs increase expression of interferon-
stimulated gene 15 (ISG15) and protein ISGylation, which are essential for maintaining their
metabolic plasticity. CRISPR-mediated ISG15 genomic editing reduces overall ISGylation,
impairing PaCSCs self-renewal and their in vivo tumorigenic capacity. At the molecular level,
ISG15 loss results in decreased mitochondrial ISGylation concomitant with increased accu-
mulation of dysfunctional mitochondria, reduced oxidative phosphorylation (OXPHOS) and
impaired mitophagy. Importantly, disruption in mitochondrial metabolism affects PaCSC
metabolic plasticity, making them susceptible to prolonged inhibition with metformin in vivo.
Thus, ISGylation is critical for optimal and efficient OXPHOS by ensuring the recycling of
dysfunctional mitochondria, and when absent, a dysregulation in mitophagy occurs that
negatively impacts PaCSC stemness.
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Pancreatic ductal adenocarcinoma (PDAC) is currently thefourth most frequent cause of cancer-related deathsworldwide, and is projected to become the second deadliest
cancer by 2030 (ref. 1). Clinically, since PDAC often goes unde-
tected2, patients are typically diagnosed at late stages, when
therapeutic intervention only slightly improves overall survival
beyond 6 months and very rarely result in long-term (>5 years)
progression-free survival3. Thus, in light of decades of research,
effective therapies for this disease remain limited.
In order to achieve advancements, it is important to appreciate
that pancreatic tumors are extremely heterogenous4. Among this
heterogenous population of cells exists the so-called cancer stem
cell (CSC), that not only drives tumor heterogeneity by giving rise
to all of the other cancer cells (i.e., non-CSCs) present within the
tumor, but is also responsible for post therapeutic disease relapse.
Therefore, eliminating this subpopulation of stem-like tumor cells
may represent the only successful strategy to treat PDAC.
Unfortunately, the evolving concept that non-CSCs can convert
into CSCs when the latter are directly eliminated highlights that
CSC-specific-targeted therapies will likely not be effective on their
own5,6. Likewise, CSCs themselves are extremely plastic and can
efficiently adapt to intrinsic and extrinsic insults or stress7,
reinforcing the need to better understand the factors that mediate
their plasticity and the CSC state. An example of CSC plasticity,
and one that may be therapeutically exploited, is metabolic
plasticity8. We and others have shown that PaCSCs can meet
their energy requirements via mitochondrial oxidative phos-
phorylation (OXPHOS) or, conversely, they can switch to gly-
colysis based on specific environmental conditions or insults9,10.
Moreover, we identified two subpopulations of PaCSCs that
coexist but with different metabolic phenotypes: one being
OXPHOS-dependent with full stemness, and the other displaying
a more plastic phenotype, at the expense of reduced self-renewal
and tumorigenicity10. The latter was experimentally shown to be
the subpopulation responsible for the development of in vivo
resistance to metformin, an inhibitor of complex I of the mito-
chondrial electron transport chain (ETC)11. Our and other stu-
dies now confirm that these plastic cells are capable of
overcoming the inhibitory effects of mitochondrial inhibitors, by
switching to anaerobic glycolytic metabolism9,10,12,13. Thus, if
CSC plasticity could be effectively targeted, therapies that mod-
ulate CSC metabolism would be more effective.
In general, cellular plasticity or cell fate transitions involve rapid
changes in gene expression patterns and/or protein post-
translational modifications (PTMs). Regarding the latter, PTMs
have been shown to be involved in cell fate decisions; however,
their relevance in CSC plasticity remains underexplored. One of
the best studied PTM processes is ubiquitination, a covalent PTM
that conjugates ubiquitin (Ub) to lysine residues on protein sub-
strates, regulating their stability and function. Ubiquitination and
de-ubiquitination are the major cellular processes used to balance
the protein turnover of several transcription factors that regulate
stem cell differentiation14, and the proper coordination of ubi-
quitylation and deubiquitylation is necessary for efficient stemness
and differentiation15. Moreover, ubiquitination is a critical reg-
ulatory process in several metabolic processes such as mitophagy,
the removal of damaged mitochondria via a selective form of
autophagy. Apart from removing dysfunctional mitochondria,
mitophagy is also necessary for proper cellular functions and cell
fate determination16,17, and an increasing number of studies
suggest that alterations in mitophagy can severely impact (stem)
cell phenotypes and cellular plasticity16,18. Thus, PTMs can affect
cellular plasticity or cell fate transitions at multiple levels.
In addition to Ub, Ub-like (UbL) modifiers also play an
important role in PTMs and mitophagy. The best-known UbL
modifier is SUMO, which has been implicated in a wide range of
cellular processes, including cell identity and cancer progres-
sion19, as well as mitochondrial dynamics20. With more and more
studies linking Ub and UbL modifiers to cell fate determination
and metabolic plasticity, it is highly plausible that Ub- and UbL-
mediated PTMs may also participate in CSC identity and plas-
ticity. In the present study we determine the expression of UbL
modifiers in PaCSCs and discover that the UbL modifier
Interferon-stimulated gene 15 (ISG15), specifically its PTM pro-
cess known as ISGylation, is upregulated in PaCSCs and is a
necessary key process for PaCSC stemness, tumorigenesis and
metabolic plasticity.
Results
ISG15 is enriched in PaCSCs and predicts patient survival.
RNA sequencing (RNA-seq ArrayExpress: E-MTAB-3808) of
PaCSCs previously showed upregulation of genes involved in
OXPHOS, linking mitochondrial respiration to PaCSC stem-
ness10. Further probing of the PaCSC transcriptome revealed
enrichment of the Ub-mediated proteolysis pathway in PaCSCs
(Fig. 1a). Since modulation of Ub and Ub-related enzymes in
CSCs has been previously described and extensively studied21, we
asked whether the less well-studied family of UbL modifiers, in
the context of CSCs, were also differentially expressed. RTqPCR
analysis revealed that ISG15, SUMO, NEDD8, and FAT10 were
significantly increased in CD133+ versus CD133– cells (tradi-
tional CSC marker), highlighting that increased transcription of
UbL genes takes place in PaCSCs (Fig. 1b).
We recently published that ISG15 secreted by tumor-associated
macrophages (TAMs) can activate PaCSCs via a paracrine
mechanism of action22; however, the expression and role of
endogenous ISG15 and ISGylation in PaCSCs has not been
analyzed to date. Enrichment for PaCSCs using various
approaches, including chemoresistance, growth as spheres or
fluorescence-activated cell sorting (FACS) for the CSC markers
CD133 or autofluorescence23, revealed increased ISG15 messen-
ger RNA (mRNA) levels, increased monomeric ISG15 (mon-
ISG15) protein levels, and increased protein ISGylation in
PaCSCs versus non-PaCSCs (Fig. 1c and Supplementary Fig.
1a–c), indicating a CSC-specific enrichment. ISG15 expression is
regulated by Type I IFNα/β receptor (IFNAR)-mediated signaling
and similar to ubiquitination, ISGylation is regulated by an E1-
E2-E3 enzymatic cascade24. We have previously shown that Type
I IFN signaling is activated in PaCSCs, and PaCSCs secrete
functional IFN-β22. Accordingly, we observed that CSC-enriched
sphere cultures expressed higher levels of the ISG15 transcrip-
tional regulators pSTAT1 and IRF9 (Supplementary Fig. 1d),
which are downstream of the IFNAR. Higher mRNA levels of the
E1-activating enzyme Ube1L, E2-conjugating enzyme Ube2L6
and E3 ligase Herc5 were also observed (Supplementary Fig. 1e),
indicating that the ISG15/ISGylation pathway is activated in
PaCSCs.
Using the publicly available transcriptome data sets (GSE62165
(ref. 25), META data set26, and GSE71729 (ref. 27)), ISG15
transcriptional levels were evaluated. Importantly, since ISG15
is also expressed by TAMs in the tumor microenvironment
(TME)22, the META data set [consisting of four published PDAC
gene expression studies (n= 108) including data sets with tumor
cellularity >35% (GSE32688) or micro-dissected samples
(GSE15471)] and the Moffitt series [which applies a virtual
microdissection approach to identify distinct tumor- and stroma-
specific signatures] allowed for the identification of genes
preferentially overexpressed in tumor epithelia. For all data sets,
ISG15 mRNA levels were significantly elevated in tumor samples
or metastases versus adjacent normal tissue (Fig. 1d and
Supplementary Fig. 2a, b). In addition, tumors of the basal
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subtype, having a worse prognosis28, expressed significantly
higher levels of ISG15 compared to classical subtype tumors, but
no significant difference in ISG15 expression was observed across
stromal subtypes, although a marked increase was appreciated in
activated stroma (Supplementary Fig. 2c, d). For the GSE71729
(ref. 27) and Bailey28 series, well-annotated clinical data is
available and was used to show in both data sets a clear deviation
and significant decrease in median overall survival for ISG15
high-expressing patients compared to ISG15 low-expressing
patients (Fig. 1e). Lastly, quantification of secreted ISG15 in
serum revealed significantly increased levels in PDAC patients
versus healthy controls, and a clear correlation with disease
progression (Fig. 1f). Altogether, these results confirm the clinical
relevance of ISG15 in PDAC.
ISG15 expression is linked to mitochondria-related pathways.
Next, GSEA comparing the samples belonging to the top and
bottom quartiles of ISG15 expression was performed using the
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collection, we observed significantly and commonly enriched IFN
and stem-associated pathways across both series, including TGF-
β, mTOR, KRas, IL-6/JAK/STAT3, and PI3K/AKT/MTOR, as
well as epithelial to mesenchymal transition (EMT) signaling
(Fig. 2a and Supplementary Fig. 3a, b). Interestingly, OXPHOS-
associated genes were also significantly enriched (Fig. 2a, b and
Supplementary Fig. 3a, b). Since ISG15 has been previously
associated with mitochondria29,30, and based on our published
findings associating PaCSC stemness with mitochondrial
respiration10, we FACS separated PDX-derived cells based on the
expression of the CSC marker autofluorescence23 and mito-
chondrial mass using MTDR (Fig. 2c). WB analysis revealed that
double-positive cells had the highest levels of mono-ISG15 and
ISGylated proteins (Fig. 2d). In addition, double-positive cells
expressed high ISG15 and KLF4 and low CMYC mRNA levels
(Fig. 2e), correlating with established PaCSC molecular pheno-
types10,31. Since these results suggested a possible link between
ISG15 and mitochondria, mitochondria from adherent and
sphere-derived cultures were enriched for and ISG15/ISGylation,
in addition to mitochondria-specific proteins, were determined by
WB analysis. As suspected, mitochondria from PaCSC-enriched
cultures contained more mono-ISG15 and ISG15-conjugated
proteins compared to mitochondria from non-CSC-enriched
adherent cultures (Fig. 2f). A similar increase was observed in the
cytosolic fraction, consistent with our initial observations (Fig. 1c
and Supplementary Fig. 1c). Finally, when ISG15 was edited using
CRISPR-Cas9, a marked decrease in mono-ISG15 and ISG15-
conjugated proteins in both the mitochondrial and cytosolic
fractions was achieved (Fig. 2f).
Loss of ISG15/ISGylation affects CSC functional properties. To
assess the molecular and functional consequences of ISG15 loss
on PaCSCs, we used CRISPR-Cas9 to target ISG15 in Panc185
and Panc354 and established stably-edited polyclonal cultures (in
order to maintain the heterogeneity of the primary culture)
(Fig. 3a). While the loss of ISG15 had no significant effect on
proliferation, the expression of pluripotency-associated tran-
scripts, or pERK1/2 protein levels (Fig. 3b and Supplementary
Fig. 4a, b), the expression of well-established CSC markers was
modulated, but varied between cell lines. The expression of the
well-established marker CD133 was not affected upon ISG15 loss
in Panc185 or Panc354 (Fig. 3c), while other markers, such as
ALDH1, SSEA1, SSEA4 and CD24 were reduced but not always
in both cell lines (Supplementary Fig. 4c). These data indicate
fluctuations but not elimination of the CSC population(s) upon
edition of ISG15. In contrast, when we employed a functional
CSC readout assay (i.e., side population) we observed a consistent
and significant reduction in both ISG15CRISPR cultures (Fig. 3d).
To further functionally characterize the consequence of ISG15
loss on the PaCSC population, we assessed sphere formation
capacity and measured significantly lower self-renewal in
ISG15CRISPR cells across multiple generations (Fig. 3e).
ISG15 has both autocrine and paracrine functions32. We
reported that PaCSCs can secrete free ISG15, which may act
directly on PaCSCs via an autocrine mechanism of action, or on
other TME cells via paracrine signaling22. Indeed, when PaCSCs
were treated with recombinant ISG15 (rISG15), we pre-
viously observed increased self-renewal capacity, pERK1/2 signal-
ing and intracellular ISGylation22; however, whether rISG15
entered directly into the cell to ISGylate proteins or acted through
a receptor-mediated signaling cascade was not determined.
Importantly, neither the self-renewal capacity of Panc185-
ISG15CRISPR cells, intracellular ISGylation or pERK activation
was restored following treatment with rISG15 (Supplementary
Fig. 5a–d), indicating that rISG15 signaling is likely receptor-
mediated and its ability to enhance ISGylation is dependent on
endogenous ISG15. Thus, loss of ISGylation rather than loss of
ISG15 autocrine signaling negatively impacts PaCSC functional
properties, as free ISG15 cannot rescue ISG15CRISPR cells.
Tumorigenesis is a hallmark of CSCs, and consistent with
reduced sphere formation capacity, Panc185-ISG15CRISPR cells
exhibited significantly reduced tumor growth and a marked
reduction in tumor take when <10,000 cells were injected (Fig. 3f).
Of note, the Panc185-ISG15CRISPR tumors that did form with
10,000 or 1000 cells were not a result of outgrowth of ISG15-
positive cells as demonstrated by WB analysis of human ISG15
performed on explanted tumors (Fig. 3g and Supplementary Fig.
6a). Importantly, similar results were obtained with Panc354-
ISG15CRISPR cells (Supplementary Fig. 6b, c). We then performed
in vivo extreme limiting dilution assays (ELDA) with 10,000,
1000 and 100 cells, and calculated a 3.45-fold reduction in CSC
numbers in the absence of ISG15 (Fig. 3i). This reduction in
tumor numbers, sizes and weights coincided with reduced
kinetics in tumor take, with ISG15CRISPR tumors appearing later
in time (Supplementary Fig. 6d). Finally, the reduced tumorigenic
potential of Panc185-ISG15CRISPR cells could be partially rescued
by overexpression of a V5-tagged ISG15 construct (Fig. 3f, i and
Supplementary Fig. 6e). Altogether, these findings indicate a
central role for ISG15/ISGylation in the maintenance of PaCSCs
in vivo.
To identify key cellular pathways altered by ISG15 loss,
RNAseq analysis was performed on ISG15CRISPR sphere-derived
cells. We observed downregulation of genes belonging to key CSC
pathways, including MYC, OXPHOS, MTORC1, P53, IL-6/JAK/
STAT3, as well as EMT signaling (Supplementary Fig. 7a, b).
Interestingly, genes associated with KRas, Hedgehog, TGF-β and
Fig. 1 Ub and UbL pathways are enriched in PaCSCs and predict survival. a Ubiquitin pathway enrichment plots from RNAseq analysis (ArrayExpress: E-
MTAB-3808) of sphere and adherent cultures (CSCs and non-CSCs, respectively) derived from five different primary PDX PDAC cultures. b Mean relative
mRNA levels ± sd of UbL modifiers ISG15, SUMO, NEDD8, and FAT10 in CD133+ and CD133– cells sorted from Panc185 spheres. Data are normalized to β-
Actin mRNA expression. (n= 4 biologically independent sortings; **p= 0.0058; ***p < 0.001, as determined by Student’s t-test). c Western blot (WB)
analysis of monomeric (mon)-ISG15 and ISG15-conjugated proteins in non-CSCs [adherent (adh), Fluo- and CD133–] versus CSCs [spheres (sph), Fluo+
or CD133+ ] from indicated PDX-derived cultures. Interferon (IFN)-treated Panc354 cells was used as positive control and tubulin as a loading control.
Molecular weight markers kDa Mr(K) are shown. d Box and Whisker Plots showing the differential expression of ISG15 in normal adjacent (Adj.) tissue
versus PDAC tumors and metastasis (met) in three independent transcriptomic data series: GSE62165 (13 Adj. normal, 118 tumors), META data set
(70 Adj. normal, 108 tumors), GSE71729 (45 Adj. normal, 145 tumors, 61 mets). Rectangles show the first quartile, the median, and the third quartile. The
two whiskers indicate the minimum and maximum values, and outliers are depicted as circles (unpaired two-sided Student’s t-test). e Kaplan–Meier curves
showing the overall survival of PDAC patients in two independent data series: GSE71729 (n= 145) and Bailey (n= 96), stratified according to the median
value of ISG15 expression. HR hazard ratio. A Log-rank test was performed for survival analysis and a Cox Proportional Hazard regression model to
calculate HRs. f Mean ISG15 protein levels (pg/mL) ± sem present in serum form healthy (hth) (n= 21), resectable (res) (n= 14), locally advanced (LA)
(n= 17), and metastasis (met) (n= 19) patients. *p < 0.05; ***p < 0.001; ns, not significant, as determined by one-way ANOVA with Bonferroni’s multiple
comparisons test.
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Bailey data series













































































































































Fig. 2 ISG15 expression is linked to mitochondria-related pathways. a Gene sets enriched in the transcriptional profile of tumors belonging to the top
ISG15 high-expression group, compared with the bottom expression group in the Bailey data series. Shown are the NES (normalized enrichment score)
values for each pathway using the Hallmark genesets, meeting the significance criteria: nominal p-value of <0.05, FDR < 25%. b Enrichment plot for
OXPHOS signaling in ISG15 high versus low. c Autofluorescence (CSC) and Mitotracker Deep Red (MTDR, approximation of mitochondrial mass) were
combined to sort the four gated populations (Q1–Q4) from Panc185 spheres. d WB analysis of ISG15 protein expression in the four FACS sorted
populations in c. Tubulin was included as a loading control. e RTqPCR analysis of CMYC, KLF4 and ISG15 gene mean fold change ± sd in the four FACS
sorted populations in c (n= 3 replicates from one independent sorting experiment). Values compared to Q1, set as 1.0. f WB analysis of ISG15 protein
expression in mitochondrial and cytosolic fraction from Panc185 Control or CRISPR-Cas9 ISG15-edited (ISG15CRISPR) CSCs (sph) and non-CSCs (adh). The
membrane was additionally blotted for mitochondria OXPHOS complex proteins using the Mitoprofile Total OXPHOS antibody cocktail in addition to
GAPDH (loading control). Shown are bands corresponding to Complex (C)V, CIII, CII, CIV, and CI. Total ISG15 expression [ISG15-conjugated and
monomeric (mon-) proteins] for each sample was quantified by densitometric analysis and fold changes are shown, relative to control adherent (adh), set
as 1.0 for both mitochondria and cytosolic fractions.
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Fig. 3 Loss of ISG15/ISGylation affects PaCSC functional properties. a WB analysis of mon-ISG15 and ISG15-conjugated proteins after CRISPR-Cas9
ISG15 editing (CRISPR) in two different primary PDAC PDX cultures. Tubulin was used as loading control. b Proliferation of control and ISG15CRISPR
Panc185 and Panc354 cells, graphed as mean cell numbers ± sd determined at the indicated days post seeding (n= 3 biologically independent samples).
c Representative flow cytometry plots for CD133 expression in control and ISG15CRISPR Panc185 and Panc354 cells. d Mean percent of Hoechst non-
retaining cells (i.e., side population) ± sd in control and ISG15CRISPR Panc185 and Panc354 cells (n= 3 biologically independent samples; *p= 0.0227;
****p < 0.0001, as determined by Student’s t-test). e Mean fold change ± sd of 1st, 2nd, and 3rd generation (gen) sphere formation capacity of control
versus ISG15CRISPR cells (Panc185: n= 3 biologically independent samples; *p= 0.0230; **p= 0.0044; ns not significant, as determined by Student’s
t-test; and Panc354: n= 3 biologically independent samples; *p= 0.0482; **p= 0.0090; ns, not significant, as determined by Student’s t-test). Control set
as 1.0. f Images of tumors obtained after injection of 104 and 103 Panc185 control, ISG15CRISPR and ISG15Rescue (ISG15CRISPR+ ISG15-V5-GFP, E1, E2, and E3
overexpression) (Rescue) cells. g WB analysis of mon-ISG15 and ISG15-conjugated proteins in freshly digested 104 tumors obtained from f. GAPDH was
used as loading control. h–i Average tumor weights ± sem (n= indicated in i; *p= 0.0172; ns, not significant, as determined by Student’s t-test; nd, not
determined) (h) and total number of tumors obtained from control, ISG15CRISPR and ISG15Rescue injections from three independent in vivo ELDA animal
experiments (i). CSCs frequencies were calculated using the Extreme Limiting Dilution Analysis software.
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WNT signaling were significantly increased (Supplementary Fig.
7a). RNA-seq analysis of ISG15CRISPR cells highlighted a link
between ISG15 and EMT, mitochondria and mitochondrial
metabolism. We have previously shown that macrophage condi-
tioned media (MCM) from M2-polarized macrophages can
induce a mesenchymal transition in PaCSCs at the morphological
and transcriptional level22. Along these lines we observed that
treatment of PDAC cells with MCM also increases ISG15 mRNA
levels, suggesting that ISG15 expression may play a role in PDAC
EMT, invasion and/or migration (Supplementary Fig. 8a). EMT-
associated morphological, transcriptional and migratory changes
were evaluated in control and ISG15CRISPR cells in the presence of
EMT promoting factors. Loss of ISG15 had no effect on the
capacity of cells to assume a more elongated mesenchymal
morphology, nor was there a consistent effect on the expression
of EMT genes or migration in the presence of MCM or oncostatin
M (Supplementary Fig. 8b–e). Thus, ISG15 seems not to be an
EMT master regulator and its loss does not abrogate the capacity
of PDAC cells to undergo EMT.
Loss of ISG15/ISGylation alters mitochondrial metabolism. We
next turned our attention to the mitochondria. Transmission
electron microscopy (TEM) images of PaCSC-enriched sphere
cultures consistently revealed more mitochondria per cell in
ISG15CRISPR cells compared to control cells, suggesting an
increase in mitochondria numbers upon ISG15 loss (Fig. 4a). The
latter was quantified by RTqPCR analysis of mtDNA, in which
ISG15CRISPR cells contained 2- to 3.5-fold more mtDNA com-
pared to control cells (Fig. 4b). Next, total mitochondrial mass
was determined using 10-N-Nonyl acridine orange (NAO),
MitoTracker™ Green (MTR-G) (Fig. 4c, d and Supplementary Fig.
9a), or MitoTracker™ Deep Red (MTDR) (Supplementary Fig. 9b,
c), and membrane potential was assessed using MitoTracker™Red
(MTR) MTR CM-H2XRos (Fig. 4e) or MTR CMX-Ros (Supple-
mentary Fig. 9d). While flow cytometric analysis using NAO
or MTDR and CM-H2XRos revealed significantly higher
mitochondrial mass and membrane potential, respectively, in
ISG15CRISPR cells, when the ratio of mitochondrial membrane
potential/mass was calculated to normalize for the higher NAO or
MTDR staining in ISG15CRISPR cells, the membrane potential in
PaCSC-enriched sphere cultures was lower or not significantly
higher (Supplementary Fig. 9e, f). Thus, while ISG15 loss
increases mitochondrial numbers and mass, the overall potential
of these mitochondria does not increase as a consequence, sug-
gesting dysfunctional mitochondria.
To functionally validate these findings, we measured the
oxygen consumption rates (OCR) of control and ISG15CRISPR
spheres in the presence or absence of distinct inhibitors of
mitochondrial function (Fig. 4f, g). Firstly, non-mitochondrial
OC was significantly lower, and baseline OCR was slightly
increased in sphere-derived ISG15CRISPR cells compared to their
control counterparts (Fig. 4f, g). We attributed the latter to
increased activity but not to increased levels of OXPHOS
complexes (Supplementary Fig. 10a, b). Secondly, maximal
respiration (i.e., FCCP-stimulated respiration) was not signifi-
cantly higher in control versus ISG15CRISPR spheres (Fig. 4g).
Using these parameters to determine the spare respiratory
capacity (SRC) (i.e., the difference between maximal respiration
and basal OCR), we observed that SRC was significantly reduced
in ISG15CRISPR cells, indicating that ISG15CRIPSR cells are less
able to overcome ATP demands under different types of
mitochondrial stress, including oxidative stress, as previously
reported by ref. 33. Taken together, these data indicated that while
ISG15CRISPR cells contain more mitochondria, they are highly
dysfunctional. In support of this claim, ATP-linked respiration
was significantly higher in ISG15CRISPR cells. This could be a
consequence of the cells attempting to confront an increased
energy demand caused by oxidative damage/stress, which is
characterized by the overproduction of reactive oxygen species
(ROS) that can damage the mitochondrial respiratory chain, alter
membrane permeability, and reduce ATP production, resulting in
higher ATP-linked respiration as a compensatory mechanism34.
ATP and ROS were measured in control and ISG15CRISPR
spheres, and in line with the aforementioned hypothesis, ATP
levels were not significantly higher in light of increased ATP-
linked OCR (Supplementary Fig. 11a). However, ROS levels were
significantly higher in ISG15CRISPR cells (Supplementary Fig.
11b), but no increase in apoptosis was observed in these cells at
any time point analyzed (Supplementary Fig. 11c). Of note, while
the increase in ROS may have affected MTR-G levels shown in
Fig. 4c35, NAO is not affected by ROS, confirming an increase in
mitochondrial mass in ISG15CRISPR cells. In addition, proton leak
was also significantly higher in ISG15CRISPR cells (Fig. 4g), which
is an additional indicator of decreased mitochondrial efficiency,
and a consequence of mitochondria responding to increasing
energy demands under oxidative damage/stress. Moreover, the
decrease in coupling efficiency observed in ISG15CRISPR cells is a
reflection of the observed increase in proton leak33 (Fig. 4g).
Lastly, we also observed decreased glycolysis and significantly
reduced glycolytic capacity in ISG15CRISPR cells (Supplementary
Fig. 12a, b). Altogether, these data strongly indicate that loss of
ISG15/ISGylation contributes to the accumulation of dysfunc-
tional mitochondria and impacts the PaCSC mitochondrial and
metabolic state.
Loss of ISG15/ISGylation reduces mitophagy. The accumula-
tion of dysfunctional mitochondria was confirmed by several
approaches. First, TEM images confirmed that mitochondria in
ISG15CRISPR cells were perinuclear, smaller and contained
deformed cristae compared to controls that contained larger
mitochondria with enlarged inner compartments and well-
defined cristae (Fig. 5a and Supplementary Fig. 13a). Immuno-
fluorescence analysis of TOM-20-stained cells revealed severe
mitochondrial fragmentation indicating increased mitochondrial
fission (Fig. 5b, c and Supplementary Fig. 13b), which is a pre-
cursor to mitophagy and an innate cellular response to aged or
dysfunctional mitochondria36. We reasoned that mitophagy-
dependent elimination of damaged mitochondria was impaired in
the absence of ISG15. Thus, mitophagic flux was assessed using
cyclosporine A (CsA), an inhibitor of mitochondrial cyclophilin
D that is commonly used to suppress mitophagy37–41, together
with MTDR staining, the latter of which should increase upon
inhibition of mitophagy (Fig. 5d, e and Supplementary Fig. 13c).
In control cells, CsA treatment for 6 h increased MTDR, which
was divided by basal MTDR levels to calculate the mitophagic
flux, as previously described37. In ISG15CRISPR cells, however,
both the increase in MTDR following CsA treatment and the
mitophagic flux were significantly reduced, confirming dysfunc-
tional mitophagy (Fig. 5d, e). To more rigorously evaluate
mitophagy under forced conditions, FCCP was used to induce
mitophagy42 and CsA, bafilomycin or chloroquine was added to
inhibit mitophagy at different levels/steps. For these experiments,
we transfected control and ISG15CRIPSR cells with pMitoKeima, a
plasmid expressing the fluorescent protein Keima tagged with a
mitochondria targeting signal peptide sequence, whose excitation
spectrum is altered by pH, indicative of mitophagosome fusion
with a lysosome. Keima fluorescence was measured by flow
cytometry in sorted pMitoKeima-positive cells, as previously
described43. In line with the mitophagic flux results, we observed
that FCCP efficiently induced mitophagy in control cells and
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when combined with the aforementioned inhibitors, Keima
fluorescence dropped. In the absence of ISG15, FCCP minimally
induced mitophagy and the effect of the inhibitors was marginal
to none (Fig. 5f), confirming that mitophagy is impaired in the
absence of ISG15.
Mitophagy is a complex process governed by several proteins,
including PTEN-induced putative kinase 1 (PINK1) and E3
ubiquitin-protein ligase parkin (PRKN)44. Notably, a 2016 study
by Im et al.29 showed that ISGylation of parkin positively
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Fig. 4 Loss of ISG15/ISGylation alters mitochondrial state and metabolism. a Transmission electron micrographs of control and ISG15CRISPR Panc185
cells. Scale bars= 2 µM. b RTqPCR analysis of fold-change in mitochondrial DNA (mtDNA) gene 12s mean copies ± sd in control and ISG15CRISPR Panc185
and Panc354 cells. Data are normalized to β-Actin expression and control set as 1.0. (n= 3 biologically independent samples; ***p < 0.0001, as determined
by Student’s t-test). c, d Representative histograms of flow cytometric analysis of NAO (10-N-Nonyl acridine orange) in control and ISG15CRISPR Panc185
and Panc354 cells c, and mean percentages ± sd in mitochondrial mass as a function of Mitotracker Green (MTR-G) and NAO (10-N-Nonyl acridine
orange) staining d (Panc185: MTR-G n= 4 biologically independent samples **p= 0.0092 and NAO n= 8 biologically independent samples ***p < 0.001,
as determined by Student’s t-test; and Panc354: MTR-G and NAO n= 3 biologically independent samples ***p < 0.001, as determined by Student’s t-test).
e Representative histograms of Mitotracker CM-H2XRos in control and ISG15CRISPR Panc185 and Panc354 cells. f Representative plot of mean Oxygen
Consumption Rate (OCR) levels ± sem, normalized to protein content, for control and ISG15CRISPR Panc185 cells, which were treated with O (oligomycin), F
(FCCP), A (antimycinA) and R (rotenone) into culture medium. Continuous OCR values (pmoles/min/µg protein) are shown. g Measured and mean
calculated parameters of OCR ± sem (n= 6 measurements per time point examined over five independent experiments; *p= 0.0148; **p= 0.0088; ***p <
0.001; *p= 0.0366; ns, not significant, as determined by Student’s t-test).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16395-2




















































































































































































































































Fig. 5 Loss of ISG15/ISGylation reduces mitophagy. a Transmission electron micrographs of control and ISG15CRISPR Panc354 cells. Scale bars= 1 or
2 µM. b Immunofluorescent images of TOM-20 in control and ISG15CRISPR Panc354 cells. Nuclei stained with DAPI in blue. Scale bars= 10 µM.
c Mitochondrial network from b displayed as a skeleton network using ImageJ skeleton filter. Scale bar= 10 µM. d Representative histograms of MTDR
expression in control and ISG15CRISPR Panc185 and Panc354 cells after 6 h of treatment with CsA (5 µM) or without (Ctl). e Mean fold change in MTDR
levels ± sd in control (Ctl)- and CsA-treated cultures (left) and mitophagic flux determined as the ratio of MTDR accumulation after CsA treatment
compared to its respective control (right) in control and ISG15CRISPR Panc185 and Panc354 cells (Panc185: n= 4 biologically independent samples; **p=
0.0013; *p= 0.0191; *p= 0.0111, as determined by Student’s t-test; and Panc354: n= 4 biologically independent samples; ***p < 0.001; ns, not significant;
**p= 0.0041, as determined by Student’s t-test). f Mean fold change in Keima protein fluorescence levels ± sem in control (red) and ISG15CRISPR (blue)
Panc185 and Panc354 cells. Cells were untreated or treated with FCCP (16 µM), with or without co-treatment with the autophagy inhibitors CsA (5 µM),
Bafilomycin (Baf; 150 nM) or Chloroquine (Chlq; 50 µM). Fluorescence in control-treated cells is set to 1.0. (n= 4 biologically independent samples for
Panc185 and n= 3 biologically independent samples for Panc354; **p < 0.01; ***p < 0.001, ns, not significant, as determined by one-way ANOVA with
Dunnett’s multiple comparison test). g Summary of average fold change in parkin levels ± sem, determined by flow cytometric analysis, in control and
ISG15CRISPR Panc185 and Panc354 cells untreated (Ctl) or treated with FCCP (16 µM) plus CsA (5 µM) for 4 h (Panc185: n= 4 biologically independent
samples; *p= 0.0283; **p= 0.0013, as determined by Student’s t-test; and Panc354: n= 4 biologically independent samples **p= 0.0084; ns, not
significant, as determined by Student’s t-test).
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anti-parkin antibody (Supplementary Fig. 14a), parkin over-
expression in PaCSCs was confirmed by flow cytometry
(Supplementary Fig. 14b). Next, parkin expression and intracel-
lular localization in the absence of ISG15 was evaluated by IF.
There was no apparent visual difference in the levels or
localization of parkin in Panc185 control or ISG15CRISPR cells
(Supplementary Fig. 14c, left); however, in Panc354-ISG15CRISPR
cells, the intracellular distribution and levels of parkin appeared
reduced compared to control cells (Supplementary Fig. 14c,
right). We confirmed the latter by flow cytometry (Supplemen-
tary Fig. 14d). We hypothesized that the observed differences
were due to accelerated parkin protein turnover in Panc354-
ISG15CRISPR cells, and experimentally showed that for both
Panc185 and Panc354, parkin degradation was accelerated in
the absence of ISG15 (Supplementary Fig. 14e). To more
rigorously evaluate parkin protein dynamics under forced
conditions, FCCP was used to induce both mitophagy and parkin
mitochondrial recruitment42, and CsA was added to inhibit
mitophagy-mediated elimination of mitochondria-bound parkin.
Flow cytometric analysis confirmed an increase in parkin
expression in control cells treated with both FCCP and CsA;
however, in ISG15CRISPR cells, parkin expression was either
unchanged or significantly decreased (Fig. 5g), confirming
reduced induction and accumulation of parkin on mitochondria
in ISG15CRISPR cells.
Autophagosomes and autophagic flux increase in the absence
of ISG15/ISGylation. TEM micrographs of control and ISG15-
CRISPR PaCSCs also revealed the presence of numerous cyto-
plasmic vesicles that contained highly electron-dense materials
(Fig. 6a and Supplementary Fig. 15a) in the absence of ISG15. As
the structures were reminiscent of phagolysosomes, we performed
IF analysis for the autophagy marker microtubule-associated
protein light chain 3 (LC3) and the lysosome marker LAMP1,
and observed LC3B and LAMP1 association and enrichment in
ISG15CRISPR cells (Fig. 6b). In addition, we used lysotracker and
acridine orange (lysosome-specific probes) and observed a con-
sistent and reproducible increase in lysosomes in the absence of
ISG15 (Supplementary Fig. 15b). While these qualitative
approaches merely suggested altered autophagy in ISG15CRISPR
cells, the autophagic flux in control and ISG15CRISPR cells was
calculated based on the amount of LC3B-II accumulation in the
presence or absence of the lysosomotropic reagent bafilomycin
A1 (Baf), which prevents the fusion of the autophagosome to the
lysosome and their subsequent degradation. LC3B-II accumula-
tion in the presence of Baf was greater in ISG15CRISPR cells
compared to control cells (Fig. 6c and Supplementary Fig. 15c),
which translated to significantly higher autophagic flux (Fig. 6d)
and indicated that ISG15CRISPR cells have modulated autophagy.
Loss of ISG15/ISGylation prevents PaCSC metabolic plasticity.
We previously showed that while PaCSCs are initially susceptible to
the mitochondrial inhibitor metformin, metabolic plasticity allows
for metformin resistant cells to emerge10. Having observed defec-
tive mitophagy and (perhaps compensatory) increased autophagy,
we set out to determine the susceptibility of ISG15CRISPR cells to
inhibitors of both autophagy and mitochondrial respiration. Fol-
lowing treatment of PaCSC-enriched sphere cultures with Bafilo-
mycin and/or Metformin, we observed that cells lacking ISG15
expression showed increased sensitivity to autophagy and mito-
chondrial respiration inhibitors (Fig. 7a). As plasticity is best
assessed in vivo, we implanted nude mice with control and
ISG15CRISPR xenografts and assessed their susceptibility to grow
over the course of 6 weeks in the presence of Metformin (Fig. 7b, c).
In line with our previously published work10, the growth of control
tumors was initially impaired in mice receiving metformin, but
resistance quickly occurred and control tumors became resistant to
metformin treatment. To our surprise, in the presence of metfor-
min, ISG15CRISPR xenograft growth was halted, no resistance
developed and sustained disease was achieved throughout the
course of the study, indicating that loss of ISG15 restrains PaCSC
metabolic plasticity (Fig. 7d–f).
Discussion
Mitochondrial function is critical and as with stem cells, likely
plays an important role in CSC biology8, by controlling numerous
cellular signaling pathways45 and regulating stemness properties
and cellular fate16. Herein, we build upon the role and association
between mitochondrial dynamics/state and PaCSCs, and report a
previously unrecognized link between ISG15/ISGylation, mito-
phagy and metabolic plasticity. While an increasing number of
studies suggest that alterations in mitochondrial dynamics and
mitophagy can severely impact (stem) cell phenotypes16–18,46, less
is known regarding the role of mitophagy in CSCs; however, it
appears as though mitophagy is also a critical biological process
for CSCs47. Ou and colleagues48 recently showed in hepatocel-
lular carcinoma that mitophagy induction increases the hepatic
CSC population while its inhibition decreases it. Likewise, Pei
et al.49 demonstrated that mitophagy is required for the self-
renewal of human acute myeloid leukemia stem cells. Thus, the
role of mitophagy in CSCs may be more biologically important
than previously recognized.
Mitochondrial dynamics and metabolism are governed by
PTMs, of which the UbL modifier ISG15 appears to be a critical
regulator in PaCSCs. In the present study we show that (1) ISG15
expression is significantly higher in PDAC tumors versus adjacent
healthy tissue, (2) ISG15 expression is higher in basal tumors and
can be used to predict survival, (3) circulating ISG15 correlates
with disease staging, and (4) PDAC patients with high ISG15
levels showed increased expression of genes associated with CSCs
pathways, including EMT and OXPHOS. Indeed, across panels of
PDX-derived primary cultures, and regardless of the separation/
enrichment method utilized, ISG15 levels and ISGylation were
consistently upregulated in PaCSCs, which we determined to be
due to innate activation of the IFN pathway (JAK/STAT signal-
ing) in PaCSCs. This is not the first time that IFN signaling has
been associated with PDAC tumors50 or PaCSCs22, highlighting
the importance of IFN signaling in PDAC. Of note, we observed a
distinct pattern of ISGylation in PaCSCs sorted for auto-
fluorescence compared to other separation methods. While
monomeric ISG15 increased in autofluorescent-positive PaCSCs,
ISG15-conjugated proteins were less abundant, suggesting that
while the levels of ISG15/ISGylation is higher in PaCSCs as a
whole, their likely exists subpopulations of PaCSCs that, when
compared, differ at the level of monomeric ISG15, ISG15-
conjugated proteins, or both.
Importantly, inhibition of ISG15/ISGylation impaired the self-
renewal and tumorigenic potential of PaCSCs, and this effect
could be partially rescued by overexpressing ISG15, but not by
treating PaCSCs with rISG15, indicating that ISGylation and not
autocrine monISG15 signaling is driving the observed effects.
Interestingly, loss of ISG15/ISGylation also had differing effects
on the expression of CSC markers, such as CD133, SSEA1, CD24,
or ALDH1. For example, CD133 levels were not affected, while
ALDH1 levels were only reduced in Panc354 cells. However,
when cultures were subjected to functional CSC assays, such as
Hoechst retention (i.e., side population), sphere formation or
tumorigenesis, ISG15 was determined to be necessary. We con-
clude that ISG15 loss does not eliminate the CSC population,
but rather abolishes their functional properties rather than
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their molecular phenotypes (expression of CSC markers or
pluripotency-associated genes). Thus, unless placed in an envir-
onment that requires a functional stem-like behavior, the loss of
ISG15 has no dominant phenotype.
RNAseq analysis revealed a significant decrease in key stem
pathways upon loss of ISG15/ISGylation, including EMT and
OXPHOS. EMT has been linked to stemness, and Desai et al.51
have shown that aberrant activation of the ISG15 pathway confers
a motile phenotype to breast cancer cells. Likewise, Farrell et al.52
showed that ISG15 overexpression in Madin-Darby kidney epi-
thelial cells promotes cell scattering and an elongated morphol-
ogy. In this study, however, no conclusive link between ISG15,
EMT and PaCSC stemness was observed. Instead, a correlation to
mitochondrial metabolism, specifically OXPHOS, was established
and confirmed through a series of metabolic-based assays. While
loss of ISG15 increased mitochondrial numbers, mass and
potential, OCR parameters were severely impaired in the absence
of ISG15. Specifically, the SRC capacity was significantly lower in
ISG15CRISPR cells, indicating that these mitochondria were
metabolically and energetically defective (i.e., dysfunctional).
Cells use mito-fusion, mito-fission, and mitophagy to con-
stantly remodel the mitochondrial network and to isolate and
selectively eliminate aged, superfluous or unhealthy/damaged




















































































Fig. 6 Autophagosomes and autophagic flux increase in the absence of ISG15/ISGylation. a Transmission electron micrographs of control and
ISG15CRISPR Panc185 cells. Scale bars= 5 or 2 µM. b Immunofluorescent images of LC3B (red) and LAMP1 (green) in control and ISG15CRISPR Panc185 cells.
Nuclei stained with DAPI in blue. Scale bar= 10 µM. c WB analysis of LC3B in control and ISG15CRISPR cultures untreated (Ctl) or treated with the
autophagy inhibitor Bafilomycin (Baf) for 5 h. Tubulin was used as loading control. dMean fold change ± sd in autophagic flux determined by densitometric
quantification of LC3B-II accumulation after autophagy inhibitor addition, subtracting their respective control expression levels (Panc185: n= 4
independent experiments; *p= 0.0162, as determined by Student’s t-test; and Panc354: n= 3 independent experiments; *p= 0.0143, as determined by
Student’s t-test).
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interconnected events guarantees homeostatic balance16,53.
Mitophagy is a complex process and involves many cellular fac-
tors44, with PINK1 and PARKIN representing the two most
important mediators of mitophagy. We observed extreme mito-
chondrial fission and fragmentation in the absence of ISG15,
indicating that the precursor events to mitophagy were activated;
however, the completion of the mitophagic process was impaired,
resulting in the inability of PaCSCs to eliminate their dysfunc-
tional and unhealthy mitochondria. It is important to note that
autophagy was increased, indicating that mitophagy-specific
factors are impaired in cell lacking ISG15. While the mechan-
ism(s) behind how ISG15 participates in mitophagy have not
been elucidated in this study, we observed a potential link
between ISGylation, parkin and mitophagy. We show that PaCSC
mitochondria are ISGylated, PaCSCs express higher levels of
parkin compared to non-CSCs, and in the absence of ISG15, the
long-term stability of parkin is modulated. During mitophagy,
parkin binds to dysfunctional mitochondria and it has been
previously shown that ISGylation of parkin positively regulates its
ubiquitin E3 ligase activity29. In our experiments, we show that
during induced mitophagy with FCCP, parkin levels do not
increase in the absence of ISG15. Thus, we hypothesize that
parkin cannot effectively complete the mitophagic process either
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Fig. 7 Loss of ISG15/ISGylation prevents PaCSC metabolic plasticity. a Quantification of the average percentage ± sd of cells in early apoptosis (Annexin-
V+ ), late apoptosis (Annexin-V+ /DAPI+ ) and dead (DAPI+ ) from control and ISG15CRISPR sphere cultures after 3 days of treatment with Bafilomycin
(1 nM, Baf, B) and/or Metformin (10 µM, MET, M) (n= 3 biologically independent samples; *p < 0.05; **p < 0.01; ***p < 0.001, as determined by Student’s
t-test). b Experimental set-up for in vivo experiments using subcutaneously implanted control and ISG15CRISPR tumors (xenografts) and treatment with
Metformin (MET). c WB analysis of mon-ISG15 and ISG15-conjugated proteins in freshly digested donor tumors obtained from control and ISG15CRISPR
injected cells, used for tumor implantations in b. d Average fold change in tumor volume ± sem in control and ISG15CRISPR xenografts with or without
Metformin (MET) treatment over the course of 42 days (n= 6 tumors/group examined over two independent in vivo animal experiments; ***p < 0.001; ns,
not significant, as determined by Student’s t-test). e Average tumor weights ± sem obtained at sacrifice from d (**p= 0.0099; ns, not significant, as
determined by Student’s t-test). f Representative images of tumors at the end of the experiment.
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ISG15. Further experiments are necessary to validate this
hypothesis. Nonetheless, understanding that mitophagy is an
important quality control mechanism necessary for the recycling
of OXPHOS-active mitochondria, PaCSCs preferentially use
mitochondrial OXPHOS to meet their energy requirements and
oncogenic transformation increases cellular stress and mito-
chondrial damage, then it is plausible to assume that activation of
mitophagy and the clearance of dysfunctional mitochondria is an
important requisite for the maintenance of the PaCSC pool. Thus,
its inhibition would, at a minimum, affect CSC functionality and
perhaps other key processes such as plasticity.
In addition to OXPHOS, glycolysis as well as glycolytic capa-
city and reserve were also significantly impaired in PaCSCs in the
absence of ISG15, suggesting that the overall metabolic plasticity
of PaCSCs (aerobic and anaerobic respiration) was affected by
ISG15/ISGylation loss. Indeed, the latter was shown in vivo using
metformin. While we have previously shown that PaCSCs are
sensitive to metformin, resistance inevitably occurs due to the
presence of plastic CSCs capable of shifting their metabolism
towards glycolysis10. In the absence of ISG15, however, tumors
were unable to proliferate and acquire resistance to metformin,
which confirms that loss of ISG15 impedes the metabolic plasti-
city of PaCSCs. Thus, this study highlights a direct link between
ISG15/ISGylation and metabolic plasticity in PaCSCs, and
strongly argues for further research into the development of
inhibitors of ISG15/ISGylation for PDAC. It is important to note
that our silencing strategy does not discriminate between mono-
ISG15 and ISGylation, thus further studies are still needed to
determine whether the observed effects are due to mono-ISG15,
ISGylation or both. Finally, it is likely that other UbL modifiers
are also important for the biology of PaCSCs and that ISG15/
ISGylation may also be affecting other key processes due to
additional PTMs; therefore, the study of UbL modifiers and UbL-
mediated PTMs in CSCs in general is also warranted by the work
detailed in this study.
Methods
Cell lines and primary human pancreatic cancer cells. HPDE cells were kindly
provided by Francisco Real (CNIO) and maintained in DMEM/F12 (Gibco) sup-
plemented with B27 1:50 (Invitrogen, Thermo Fisher Scientific, Europe), 20 ng/mL
bFGF (Pan-Biotech, GmbH, Aidenbach, Germany) and 50 U/mL penicillin/strep-
tomycin (Invitrogen). PDAC patient-derived xenografts (PDAC PDX) were
obtained from Dr. Manuel Hidalgo under a Material Transfer Agreement with the
Spanish National Cancer Center (CNIO), Madrid, Spain (Reference no.
I409181220BSMH). To establish low-passage primary PDAC PDX-derived in vitro
cultures, xenografts were minced, enzymatically digested with collagenase (Stem
Cell Technologies) for 60 min at 37 °C and after centrifugation for 5 min at 500 × g,
the cell pellets were resuspended and cultured in RPMI (Invitrogen) supplemented
with 10% fetal bovine serum (FBS; Invitrogen), 50 units/mL penicillin/strepto-
mycin and fungizone (Invitrogen). PDAC PDX-derived cultures are referred to by
a random number designation (e.g., Panc185 or Panc354). Primary cultures were
tested for Mycoplasma at least every 4 weeks.
Macrophages conditioned medium. For macrophage conditioned medium
(MCM), human blood was obtained from healthy donors, and peripheral blood
mononuclear cells (PBMCs) were isolated from buffy coats following standard
protocols22. This study received the approval of the Committee of Ethics and
Clinical Investigation of the Universidad Autónoma de Madrid, Spain. Monocytes
were cultured under adherent conditions in RPMI medium (Invitrogen) supple-
mented with 10% FBS (Invitrogen) or human AB serum (Sigma, Spain) in a
humidified atmosphere with 5% CO2 at 37 °C. Adherent monocytes were cultured
for 7 to 10 days to allow for differentiation into macrophages.
Gene expression data sets and GSEA analyses. The gene expression data sets
used in this study are publicly available. The data set from Janky et al.25 was
downloaded from GEO (GSE62165); the data set from Moffitt et al.27 was
downloaded from GEO (GSE71729); the data set from Bailey et al.28 was included
in a supplementary figure of their published work; and the META data set, con-
taining data sets GSE15471, GSE16515, GSE22780, and GSE32688, was generated
as described in ref. 26. The samples included in the top and bottom quartile of
expression of ISG15 were compared in GSEA, using the Hallmark gene-set
database. The GSEA module of the Genepattern suite from the Broad Institute was
used, with 1000 permutations and FDR < 25% was considered statistically
significant.
Kaplan–Meier analysis of gene expression microarray. To analyze the prog-
nostic value of ISG15 mRNA expression, patients were stratified based on the
median value of ISG15 and survival analysis was performed with R. The two
patient cohorts were compared by a Kaplan–Meier survival plot, and the hazard
ratio with 95% confidence intervals and Log-rank p-value were calculated. The Cox
Proportional Hazard regression model was used to calculate the hazard ratio.
RStudio version 1.1.442 and R version 3.5.1 were used to generate Box and Whisker
plots and Kaplan–Meier survival plots.
Patient samples and ISG15 ELISA. Blood samples from PDAC patients and
healthy donors were provided by the BioBank Hospital Ramón y Cajal-IRYCIS
(PT13/0010/0002), integrated in the Spanish National Biobanks Network (ISCIII
Biobank Register No. B.0000678) and by Dr. Alfredo Carrato from the “Collection
of samples of the Familial Pancreas Cancer Registry” of the Carlos III Institute
(ISCIII ref no.: C.0003953). Samples were processed following standard operating
procedures with the appropriate approval of the Ethical and Scientific Committees
(Control no. No. Control: DE-BIOB-73 AC65, RG.BIOB-57, and RG.BIOB-54),
with informed consent and according to Declaration of Helsinki principles. ISG15
levels in serum samples were determined using the human ISG15 ELISA kit (E-EL-
H0203, Elabscience) as per the manufacturer’s instructions.
RNA-sequencing analysis. Total RNA was isolated by the guanidine thiocyanate
(GTC) method using standard protocols54. PolyA+ RNA fraction was processed as
in Illumina’s TruSeq RNA Sample Preparation v2 Protocol. The resulting purified
complementary DNA (cDNA) library was applied to an Illumina flow cell for
cluster generation (TruSeq cluster generation kit v5) and sequenced on the Gen-
ome Analyzer IIx with SBS TruSeq v5 reagents by following manufacturer’s pro-
tocols. RNA-seq data sets were analyzed using the tool Nextpresso55. Nextpresso is
comprises four basic levels: 1. Quality check, 2. Read cleaning and/or down-sam-
pling, 3. alignment, and 4. analysis (gene/isoform expression quantification, dif-
ferential expression, gene-set enrichment analysis and fusion prediction). Gene
signatures (Hallmark genesets) were downloaded from GSEA—Molecular Sig-
nature Database for Gene set enrichment analysis.
Sphere formation assay. Pancreatic CSC spheres were generated by culturing
primary pancreatic cancer cells (5000-20,000 cells/mL) in ultra-low attachment
plates (Corning) using FBS-free DMEM/F12 (Invitrogen) supplemented with B27
1:50 (Invitrogen), 20 ng/mL bFGF (PAN-Biotech) and 50 U/mL penicillin/strep-
tomycin (Thermo Fisher Scientific). Seven days later, spheres were harvested for
subsequent assays or counted with an inverted EVOS FL microscope (Thermo
Fisher Scientific) using a 10x objective with phase contrast. For serial passaging,
spheres were harvested using a 40-µm cell strainer, trypsinized into single cells and
re-cultured for another 7 days. Sphere counts are represented as the fold change in
spheres number/mL.
Electron microscopy analysis. PaCSC-enriched spheres were trypsinized and
centrifuge for 5 min at 400 × g. Cell pellets were fixed using a solution of 2.5%
glutaraldehyde in cacodylate buffer 0.1 M for 60 min. Cell pellets were post-fixed in
osmium tetroxide, dehydrated through ascending concentrations of ethanol and
embedded in epoxy resin. Ultra-thin sections were obtained at 0.1 μm, counter-
stained with uranyl acetate and lead citrate prior to image acquisition with a JEOL
JEM1010 (100 kV) transmission electron microscope equipped with a Gatan Orius
200 SC camera. Images were processed using DigitalMicrograph (Gatan, Inc).
Western blot analysis. Cells were harvested in RIPA buffer (Sigma) supplemented
with a protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN). Fifty
micrograms of protein were resolved by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to PVDF membranes (Amersham
Pharmacia, Piscataway, NJ). Membranes were sequentially blocked with 1x TBS
containing 5% BSA (w/v) and 0.5% Tween20 (v/v), incubated with a 1:500–1:1000
dilution of indicated antibodies (Supplementary Table 1) overnight at 4 °C, washed
five times with 1x TBS containing 0.5% Tween20 (v/v), incubated with horseradish
peroxidase-conjugated goat anti-rabbit or goat anti-mouse antibody (Amersham),
and washed again to remove unbound antibody. Bound antibody complexes were
detected with SuperSignal chemiluminescent substrate (Amersham) and images
were obtained using MyECL Imager (Thermo Fisher Scientific). Densitometry
histograms were obtained by measuring the intensity of the bands and normalized
by their housekeeping loading control by ImageJ software. For positive ISG15
induction, Interferon (IFN) was purchased from Peprotech and used at 10 U/mL
for 24 h. Blots are accompanied by the locations of molecular weight/size markers
(Mr(K)), as determined using commercially available protein ladders (Novex®-
Sharp Pre-Stained Protein Ladder Cat no. LC5800 or PageRuler™ Prestained Pro-
tein Ladders Cat nos. 26616 or 26619, all from ThermoFisher Scientific).
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Uncropped and unprocessed scans of all the main blots presented can be found in
Supplementary Fig. 16.
For autophagy flux analysis, cells were treated with the lysosomotropic reagent
Bafilomycin A1 (150 nM, Calbiochem) for 5 h or Chloroquine (50 µM, Sigma) for
72 h (ref. 56). After treatments, cells were harvested and analyzed by WB as
described above. Autophagy flux compares the LC3B-II levels with and without the
autophagy inhibitors and is calculated as the difference between of LC3B-II in the
presence and absence of the indicated inhibitor, normalized to the indicated
housekeeping protein.
Flow cytometry and FACS. Cells were resuspended in Flow buffer [1x phosphate-
buffered saline (PBS); 3% FBS (v/v); 3 mM EDTA (v/v)] before analysis with a 4-
laser Attune NxT Acoustic Cytometer (Thermo Fisher Scientific). For cell surface
marker expression, refer to antibodies listed in Supplementary Table 1. For Parkin
intracellular staining, after treating cells with 5 µM CsA (Sigma, C 3662) and 16 µM
FCCP (Sigma, C 2920) for 4 h, cells were incubated 30 min with Live/Dead Fixable
Dead Cell Stain Kit (MAN0006891, Molecular Probes) for dead cell exclusion. Cells
were fixed with 4% PFA in PBS for 10 min, washed and after o/n incubation at
4 °C, cells were permeabilized with methanol 90% in PBS for 30 min and then
incubated with an α-hu-parkin antibody (ThermoFisher Scientific) as detailed in
Supplementary Table 1. The specificity of the α-hu-parkin antibody for WB and
Flow cytometric analysis was validated using 293T cells transiently transfected with
a plasmid (pCDN3.1-Parkin) expressing the full coding sequence of parkin
(NM_004562.3), kindly provided by Drs. Raúl Sánchez Lanzas and José González
Castaño, Universidad Autónoma de Madrid, Madrid, Spain.
For Annexin-V staining, floating and attached cells were pooled and
resuspended in 1x Annexin-V staining buffer containing Annexin-V-FITC diluted
1:20 (Biotium, Freemont, CA) and incubated for 20 min at room temperature prior
to flow cytometric analysis. To evaluate chemoresistance to Bafilomycin (Baf) and
Metformin (MET), cells were treated with 1 nM and/or 10 µM, respectively, for
3 days before Annexin-V staining. For autofluorescent detection, cells were excited
with blue laser 488 nm and selected as intersection with emission filters 530/40
(BL1) and 580/30 (BL2) or, in case of sorting, emission filter for FITC. For all
assays, 2 mg/mL DAPI (Sigma) was used to exclude dead cells. Data were analyzed
with FlowJo 9.3 software (Tree Star Inc., Ashland, OR.). For cell sorting, a FACS
Vantage SE Flow Cytometer was used and data analyzed with BD FACSDiVa
software. For detection of ALDH1-positive cells, the Red-shifted Fluorescent Live
Cell Probe for ALDH (AldeRed™ 588-A ALDH Detection Assay, SCR150, Sigma),
was used according to the manufacturer’s instructions.
For mitochondrial mass and mitochondrial membrane potential measurement,
Mitotacker Green (MTR-G, M7514, Invitrogen), 10-N-Nonyl acridine orange (NAO,
A7847, Sigma Aldrich) Mitotracker Deep Red (MTDR, M22426, Invitrogen), CMX-
ROS (M7512, Invitrogen) and CM-H2XRos (M7513, Invitrogen) were used. Probes
were incubated with cells for 20min at 37 °C at a concentration of 0.1 µM, 0.1 µM, 2
nM, 10 nM, and 100 nM, respectively, and fluorescence was detected using the
filters (Ex488nm/Em530/30) BL1 for MTR-G and NAO, (Ex638nm/Em670/14) RL1
for MT-DR, (Ex561nm/Em585/16) YL1 for CMX-ROS and (Ex561nm/Em620/15)
YL2 for CM-H2XRos. For ROS production measurement, MitoSOX (M36008,
Invitrogen) was used at 1 µM for 10min at 37 °C and detected with laser (Ex561nm/
Em585/16) YL1. For lysosomes quantification, Acridine Orange (A3568, Thermo
Fisher Scientific) was incubated at 1 μg/mL for 15min at 37 °C and detected using
BL1 filter (Ex488nm/Em530/30). Alternatively, Lysotracker Deep Red (L12492,
Molecular probes, Life Technologies) was used at 1 nM for 30min at 37 °C and
detected using RL1 filter (Ex638nm/Em670/14).
To determine mitophagic flux by flow cytometry, after treatment of cells with
CsA (Sigma, C 3662) at 5 µM for 5 h, cells were trypsinized, stained with 1 nM
MTDR for 30 min and analyzed by Flow Cytometry. Mitophagy flux compares
MTDR levels with and without the mitophagy inhibitor CsA and is calculated as
the ratio of MTDR accumulation after CsA treatment compared to its respective
control (adapted from ref. 37). Examples of gating strategies for all of the
aforementioned cytometry-based analyses are presented in Supplementary Fig. 17.
Side population. Human primary PDAC cells derived from sphere cultures at a
concentration of 106 cells/mL were incubated for 30 min in the absence or presence
of the ABCG2 transporter inhibitor fumitremorgin C (5 μg/mL; Sigma) and sub-
sequently stained with Hoechst 33342 (5 μg/mL; Sigma) at 37 °C for 2 h. Cells were
washed and resuspended in cold 1x PBS. Propidium iodide (Sigma) was used to
exclude dead cells. SP cells were analyzed using a CytoFLEX Beckman Coulter
using filters NUV450 and NUV657 as previously described23.
Recombinant ISG15 experiments. Cells were seeded as spheres, as previously
described, and treated with 100 ng/mL of recombinant ISG15 (rISG15, purchased
from Abcam ab173004 and resuspended to a concentration of 1 µg/µl in water).
After 7 days, spheres were harvested in RIPA buffer for western blotting assay or
photographed and counted.
Immunostainings and confocal analysis. For immunofluorescence (IF) confocal
microscopy, cells were seeded on glass coverslips in RPMI (Invitrogen) containing
10% FBS (Thermo Fisher Scientific) at 37 °C, 5% CO2. After indicated treatments
and indicated time points, the medium was removed, cells were fixed with 4% PFA
in PBS for 20 min at room temperature, washed with PBS, permeabilized with
TritonX-100 1% in PBS for 15 min, blocked with 1% bovine serum albumin (BSA)
in PBS for 1 h at room temperature and then incubated with specific antibodies (see
Supplementary Table 1) in a solution of 1% BSA in PBS. The fluorescent images
were collected with a laser scanning confocal microscope Zeiss 710 and analyzed
using the software Leica 2009.
Lentivirus production and cell transduction. Lentiviral particles were produced
by transfection of 293T cells (Invitrogen) following a polyethylenimine (PEI)-based
protocol, as previously described57. Briefly, 5 × 106 293T cells were co-transfected
with 1 μg packaging plasmid psPAX2, 1 μg envelope plasmid pVSVG and 2 μg of
the indicated backbone plasmid: pRRL_SIN_CMV_ISG15-V5_IRES_eGFP,
pLX304_UBE1L (E1, EX-OL01733-LX304, GeneCopoeia) pRRL_SIN_CMV_U-
BE2L6_IRES_mCherry (E2), pReceiver-Lv105_Herc5 (E3, EX-Z9167-Lv105, Gen-
eCopoeia), pCAS9 or 3 different ISG15-CRISPR plasmids (Target sequences: 27
GCTGGCGGGCAACGAATTCC, 275 GCAGCAGCACCTACGAGGTA and 318
CGCTCACTTGCTGCTTCAGG cloned into pLenti-U6-sgRNA-PGK-Neo; human
ISG15 sgRNA CRISPR Lenti-vector set, K1101201, ABM, Richmond, BC, Canada)
or control scrambled sgRNA CRISPR Lenti-vector (K018, ABM). After 8 h, the
transfection medium was replaced with complete RPMI media and recombinant
lentiviruses were harvested 48 h and 72 h later. Virus particle-containing super-
natants were filtered through 0.45 µM PVDF membrane filters, aliquoted and
stored at −80 °C until needed. For lentivirus transduction, PDAC cells were seeded
in 6-well plates at a concentration of 3–5 × 105 cells/well. One milliliter of the
respective lentivirus was directly overlaid onto cells in the presence of polybrene
(Sigma) at a final concentration of 8 μg/mL. After 16 h, medium was changed and
after 48 h antibiotic selection was initiated. Stably transduced cells were obtained
after GFP- or mCherry-positive cell sorting using a FACS Vantage SE Flow Cyt-
ometer for ISG15-V5 or UBE2L6, respectively, or after antibiotic cell selection
using Blasticidin (5–10 µg/mL; Invitrogen) resistance (UBE1L or Cas9), Puromycin
(1 µg/mL; Sigma) resistance (Herc5) or G418 (500 µg/mL; Invitrogen) resistance
(ISG15-CRISPR or Control-CRISPR).
pMT-mKeima-Red. The pMT-mKeima-Red plasmid was purchased from Medical
& Biological Laboratories (MBL) CO., LTD., Japan (Cat no. AM-V0251) and used
according to the manufacturer’s instructions. Keima-Red fluorescence observed
with a short wavelength (440 nm) excitation is indicative of a neutral environment
while fluorescence observed with long wavelength (586 nm) excitation is indicative
of Keima being present in an acidic environment, which occurs upon mitopha-
gosome fusion with a lysosome. For the detection of mitophagy with Keima-Red by
flow cytometry, the protocol published by Um et al.43 was followed. Briefly, control
and ISG15CRISPR cells were transfected with 1 µg of pMT-mKeima-Red using the
Neon Electroporation Transfection system (Thermo Fisher Scientific), according to
the manufacturer’s instructions. Transfected cells were selected for with Hygro-
mycin (200 µg/mL) until stable cell lines were established. Cells were subsequently
sorted for Keima-Red fluorescense (Em 620 nm) using a FACS Vantage SE Flow
Cytometer and data analyzed with BD FACSDiVa software. For mitophagy
experiments, mitophagy was induced with 16 µM FCCP (Sigma, C 2920) and
blocked with 5 µM CsA (Sigma, C 3662), Bafilomycin A1 (150 nM, Calbiochem) or
Chloroquine (50 µM, Sigma) for 24 h. Cells were analyzed with (Ex561/Em620/15)
YL2 filter (Attune NxT Acoustic Cytometer, Thermo Fisher Scientific) to measure
Keima-Red fluorescence in an acidic environment, which occurs upon mitopha-
gosome fusion with a lysosome. Data were analyzed with FlowJo 9.3 software (Tree
Star Inc., Ashland, OR).
Mitochondria and cytosol fractionation. Cells were culture in adherence or as
spheres as described above. After 7 days, cells were harvested and mitochondria
and cytosol fractioned according to the Mitochondria Isolation Kit protocol
(89874, ThermoFisher Scientific). After isolation, mitochondria pellets were
resuspended in SDS-PAGE buffer and analyzed by WB as described above.
In vivo tumorigenicity assays. Mice were housed according to institutional
guidelines and all experimental procedures were performed in compliance with the
institutional guidelines for the welfare of experimental animals approved by the
Universidad Autónoma de Madrid Ethics Committee (CEI 60-1057-A068) and La
Comunidad de Madrid (PROEX 335/14) and in accordance with the guidelines for
Ethical Conduct in the Care and Use of Animals as stated in The International
Guiding Principles for Biomedical Research involving Animals, developed by the
Council for International Organizations of Medical Sciences (CIOMS). Briefly,
mice were housed according to the following guidelines: a 12 h light/12 h dark
cycle, with no access during the dark cycle; temperatures of 65–75 °F (~18–23 °C)
with 40–60% humidity; a standard diet with fat content ranging from 4 to 11%;
sterilized water was accessible at all times; for handling, mice were manipulated
gently and as little as possible; noises, vibrations and odors were minimized to
prevent stress and decreased breeding performance; and enrichment was always
used per the facility’s guidelines to help alleviate stress and improve breeding.
Female 6- to 8-week-old NU-Foxn1nu nude mice (Envigo, Spain) were
subcutaneously injected with 102, 103, or 104 PDAC cells expressing Cas9/Control
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sgRNA, Cas9/ISG15-CRISPR or Cas9/ISG15-CRISPR/eGFP-ISG15-V5 in 50 µl
Matrigel (Corning) per injection. Tumor growth was monitored bi-weekly for up to
4 months. Mice were sacrificed and tumors were weighed, photographed, and part
of each tumor was fixed in 4% PFA and processed for histological analysis or
mechanically digested in RIPA buffer (Sigma) supplemented with protease
inhibitor cocktail (Roche). Protein lysates were assessed for human ISG15 levels by
WB analysis as described above.
For metformin experiments, tumors were initially established by injecting 106
PDAC cells expressing Cas9/Control sgRNA or Cas9/ISG15-CRISPR in 50 µl
Matrigel (Corning) per injection in 6- to 8-week-old NU-Foxn1nu nude mice
(Envigo). Four to 5 weeks post injections, donor tumors were excised, cut into
identical pieces of ~50mm3 and implanted subcutaneously into the left and right
flanks of NU-Foxn1nu nude mice (Envigo). Three weeks following subcutaneous
tumor growth, tumors were measured, mice were randomized into treatment groups
(5 mice per group) and metformin (Alfa Aesar, ThermoFisher Scientific) treatment
was initiated (1mg/mL in drinking water) and continued for 6 weeks. Tumor
volumes were determined twice per week using a digital caliper, and drinking water
was changed every 2 days. At the time of sacrifice, tumors were excised, weighed,
photographed and fixed in 4% PFA and processed for histological analysis.
RNA preparation and real-time qPCR. Total RNA was isolated by the GTC
method using standard protocols54. One microgram of purified RNA was used for
cDNA synthesis using the Thermo Scientific Maxima First Strand cDNA Synthesis
Kit (ThermoFisher Scientific) according to manufacturer´s instructions, followed
by SYBR green RTqPCR (PowerUp™ SYBR™ Green Master Mix, ThermoFisher
Scientific) using an Applied Biosystems StepOnePlus™ real-time thermocycler
(ThermoFisher Scientific). Thermal cycling consisted of an initial 10 min dena-
turation step at 95 °C followed by 40 cycles of denaturation (15 s at 95 °C) and
annealing/extension (1 min at 60 °C). mRNA copy numbers were determined
relative to standard curves comprised of serial dilutions of plasmids containing the
target coding sequences and normalized to ß-actin levels. Primers used are listed in
Supplementary Table 2.
Proliferation assay. For proliferation assay, 35,000 cells/well were seeded in 24-
well plates in RPMI containing 10% FBS at 37 °C, 5% CO2 and triplicate wells were
counted every 24 h for 5 consecutive days.
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR)
measurements. Sphere-derived cells were plated in XF96 Cell Culture Microplates
(Seahorse Bioscience) previously coated with Cell-Tak (BD Biosciences) at a cel-
lular density of 30,000 cells/well. For OCR determination, cells were incubated in
base assay medium (D5030, Sigma) supplemented with 2 mM glutamine, 10 mM
glucose, and 1 mM pyruvate for 1 h, prior to the measurements using the XF Cell
Mito Stress Kit (Seahorse Bioscience). After an OCR baseline measurement, the
minimum oxygen consumption was determined adding 1 µM oligomycin (O) and
the maximal respiration rate was assessed by adding 1 µM FCCP (F). At the end of
the experiment the non-mitochondrial oxygen consumption was evaluated adding
both 1 µM rotenone (R) and antimycin (A). Experiments were run in a XF96
analyzer (Seahorse Bioscience), and raw data were normalized to protein content.
ATP determination assay. Lysate pellets of cells from control and Panc185-
ISG15CRISPR cells were collected to evaluate the changes in the levels of ATP. The
analysis was performed using the ATP Bioluminiscense Assay Kit CLS II (Cat. no.
11699695001, Roche) according to the manufacturer’s instructions. Bioluminis-
cence was determined using a Synergy™ HT Multi-Mode Microplate Reader
(BioTek, Winooski, Vermont, USA).
EMT induction assays. For EMT induction, Oncostatin M (OSM) (R&D systems)
was used at 100–200 ng/mL every 48 h during 4 days.
Wound-healing assay. Cells were cultured until confluence and then wounded
using a 200 µl yellow pipette tip. Cells were treated with Oncostatin M (OSM)
(R&D systems) at 100–200 ng/mL every 48 h during 4 days. Three wounds were
made for each sample, and migration distance was photographed and measured at
time 0 h and every 12 h until 48 h.
Protein half-life assay. The half-life of Parkin was evaluated incubating the cells
with 25 µg/mL of cycloheximide (CHX) dissolved in absolute ethanol. After indi-
cated time points, cells were harvested in RIPA buffer (Sigma) supplemented with a
protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN). Fifty
micrograms of protein were resolved by SDS-PAGE and western blotting was
performed as described above.
Statistical and reproducibility. Pair-wise multiple comparisons were performed
with one-way ANOVA (two-sided) with Bonferroni or Dunnett adjustment. Unless
stated otherwise, unpaired two-sided (Confidence interval of 95%) Student’s t-test
were used to determine differences between means of groups. p-values < 0.05 were
considered statistically significant. All analyses were performed using GraphPad
Prism version 6.0c (San Diego California USA).
The number of biologically independent samples are indicated in the figure
legends. Repeated independent experiments per each panel with similar results are
shown below. n= 1 (Figs. 1f, h, 2d–f, 3b, d, 4a, 5a, 6a, b, 7a, c, Supplementary
Figs. 1d–e, 4b, 5c, d, 6a, b, e, 13a, 15a); n= 2 (Figs. 1b, c, 3e, g, 4b–e, 5f, g, 7d, e,
Supplementary Figs. 1a–c, 5a, 6c, d, 8e, 10a, b, 11a, b, 14b, d, 15b); n= 3 (Figs. 3a,
5b–e, 6c, d, Supplementary Figs. 4a, 5b, 8a–d, 9a–f, 13b, c, 14a, c, e, 15c), n= 5
(Fig. 4f–g, Supplementary Figs. 11c, 12a, b).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNAseq data from Control and ISG15CRISPR Panc185 cells, generated in this study, have
been deposited in the ArrayExpress database58 at EMBL-EBI (www.ebi.ac.uk/
arrayexpress) under accession number E-MTAB-8984. Unique identifiers for the publicly
available data sets used are indicated, and source data other than those provided in the
Article or Supplementary Information are available from the corresponding author upon
reasonable request.
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